Patent intelligence · US
US 12304964
CD38 modulating antibody
CD38 modulating antibody
Patent details — US 12304964
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 20, 2025
- Expiration
- May 15, 2045
- Applicant
- BLACK BELT THERAPEUTICS LIMITED
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/627, A61K39/395
Quick answer
US 12304964 (CD38 modulating antibody) is held by BLACK BELT THERAPEUTICS LIMITED. Status: granted. Granted May 20, 2025. Expires May 15, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BLACK BELT THERAPEUTICS LIMITED
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/627, A61K39/395, A61P, A61P35/00
More from BLACK BELT THERAPEUTICS LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 12304964?
US 12304964 (CD38 modulating antibody) is held by BLACK BELT THERAPEUTICS LIMITED. Status: granted. Granted May 20, 2025. Expires May 15, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12304964?
BLACK BELT THERAPEUTICS LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 12304964 expire?
Our index shows an expiration date of May 15, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.